Facial aesthetics market led by Allergan, Galderma & Merz Pharma

Press Release   •   Aug 02, 2013 12:45 BST

The facial aesthetics market has been forecast to increase at a compound annual growth rate (CAGR) of 9.22% through to 2016, driven by the increase in the aging population, and the increasing popularity of combination therapies.

Aesthetic-minded consumers are still looking for the perfect option - one that produces a more youthful looking face, but does not require much, if any, downtime. Ideally, these consumers also would like something that offered a long-lasting effect and was delivered with minimal pain and discomfort.

Although the bar may seem to be set unrealistically high, physicians and manufacturers know that if such a treatment existed, it could potentially generate huge public interest and huge profits, which is why research in this arena continues unabated.

In a business where revenue rests heavily on out-of-pocket payments, aesthetic treatments seem more vulnerable to economic conditions, and data supports that theory. The annual survey by the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) found the average number of facelifts performed per physician decreased from 65 in 2009 to 50 in 2010.

However, the good news is the number of nonsurgical procedures is up - a direct result of patients being more educated about plastic surgery and wanting to delay surgical procedures.

Facial aesthetic products such as botulinum toxin can be used in conjunction with other cosmetic procedures such as dermal fillers, chemical peels, and microdermabrasion to improve the outcomes of facial rejuvenation.

These combinations of therapies also prevent the formation of new lines and wrinkles. Derma fillers are commonly used in combination with other procedures. When it comes to the treatment of different facial areas, botulinum toxin is generally used to treat wrinkles on the forehead and upper portions of the face, whereas dermal fillers such as Restylane are used to reduce deep glabellar folds.

These derma fillers are also often used in a complementary procedure for lower facial areas. Approximately 40-60 percent of patients are treated with a combination of both procedures. These products can also be used in combination with autologous fat transplants.

According to a recent report, 'Global Facial Aesthetics Market 2012-2016,' one of the key challenges in the market is the side effects of cosmetic surgeries caused by dermal fillers and botulinum toxins. These side effects include redness and swelling, paralysis, lumpiness, and skin necrosis.

Key players currently dominating the facial aesthetics market include Allergan Inc., Galderma S.A., Merz Pharma GmbH & Co. KGaA, and Valeant Pharmaceuticals International Inc.

For more information on the facial aesthetics market, see the latest research: Facial Aesthetics Market

Follow us on Twitter @CandMResearch issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.